A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 09 Aug 2017
At a glance
- Drugs Durvalumab (Primary) ; Oleclumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors MedImmune
- 04 Aug 2017 Planned End Date changed from 24 Apr 2023 to 15 Feb 2021.
- 04 Aug 2017 Planned primary completion date changed from 13 Nov 2020 to 15 Feb 2021.
- 18 Jul 2017 Planned primary completion date changed from 2 Oct 2020 to 13 Nov 2020.